Merck Aktie
| 121,88USD | 2,13USD | 1,78% |
WKN DE: A0YD8Q / ISIN: US58933Y1055
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 68 000 | 69 000 | 72 000 | 75 000 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,72 | 0,85 | 0,83 | 0,85 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 30 266 | 35 722 | 32 168 | 38 782 | 0 |
| Summe Anlagevermögen | 75 428 | 73 438 | 74 507 | 78 324 | 0 |
| Summe Aktiva | 105 694 | 109 160 | 106 675 | 117 106 | 0 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 67 437 | 63 102 | 69 040 | 70 734 | 0 |
| Summe Eigenkapital | 38 257 | 46 058 | 37 635 | 46 372 | 0 |
| Summe Passiva | 105 694 | 109 160 | 106 675 | 117 106 | 0 |
Adresse
| 126 East Lincoln Avenue, 07065 Rahway | |
| Telefon | +1 (908) 740-4000 |
| Internet | http://www.merck.com |
Management
|
Andre Musto
SVP & Head-Gbl Cardiometabolic & Endoc Franchise |
|
Betty D. Larson
Chief Human Resources Officer & Executive VP |
|
Brooke Hinkson
Executive Director-Global Clinical Data Standards |
|
Caroline A. Litchfield
Chief Financial Officer & Executive Vice President |
|
Chirfi Guindo
Chief Marketing Officer |
|
Christine E. Seidman
Independent Director |
|
Dalton E. Smart
Senior Vice President-Finance & Global Controller |
|
Dave Williams
Executive VP, Chief Information & Digital Officer |
|
Dean Y. Li
EVP & President-Merck Research Laboratories |
|
Denise Williams
Vice President |
|
Douglas M. Baker
Independent Director |
|
Fiona Hamilton Marshall
Senior VP & Global Head-Discovery Sciences |
|
Inge G. Thulin
Independent Director |
|
James Matteucci
Associate Director-State Government Affairs |
|
Jannie Oosthuizen
President-Merck Human Health |
|
Jennifer Zachary
Executive Vice President & General Counsel |
|
Johanna Herrmann
Vice President-Global Communications |
|
Joseph Romanelli
President-Human Health International |
|
Kathy J. Warden
Independent Director |
|
Kelly E. W. Grez
Secretary |
|
Marjorie C. Green
SVP, Head-Oncology & Global Clinical Development |
|
Mary Ellen Coe
Independent Director |
|
Pamela Eisele
Head-Product, Pipeline & Supply Media Relations |
|
Pamela J. Craig
Independent Director |
|
Patricia Fiorello Russo
Independent Director |
|
Paul B. Rothman
Independent Director |
|
Peter Dannenbaum
Vice President-Investor Relations |
|
Richard R. DeLuca
Executive Vice President & President-Animal Health |
|
Risa J. Lavizzo-Mourey
Independent Director |
|
Robert M. Davis
Chairman, President & Chief Executive Officer |
|
Sanat Chattopadhyay
EVP & President-Merck Manufacturing Division |
|
Stephen L. Mayo
Independent Director |
|
Steven Graziano
Director-Business Development |
|
Surendralal Lanca Karsanbhai
Director |
|
Sylvia A. Ayler
Legal Director |
|
Thomas Henry Glocer
Lead Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.